Methotrexate on a 21-Day Cycle for Low-Risk Gestational Trophoblastic Neoplasia

作者：Diaz Juan; Thomas M Bijoy; Paz Pabon Charlotte; Hernandez Enrique^*

来源：Journal of Reproductive Medicine, 2012, 57(9-10): 411-414.

• chemotherapy
• gestational trophoblastic neoplasia
• methotrexate

OBJECTIVE: To perform an outcome analysis of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with a 5-day intramuscular methotrexate (MTX) regimen on a 21-day cycle. %26lt;br%26gt;STUDY DESIGN: A retrospective review of 31 patients with low-risk GTN treated with a 5-day MTX regimen. %26lt;br%26gt;RESULTS: A total of 31 patients with low-risk GTN (WHO score %26lt;7) received single-agent MTX at a dose of 0.4 mg/kg daily for 5 days every 21 days (mean number of cycles, 3; 83% remission). The only significant toxicity encountered was grade 2 stomatitis in 8 (26%) patients. %26lt;br%26gt;CONCLUSION: A 5-day MTX regimen given every 21 days is convenient, well-tolerated and effective for patients with low-risk GTN. (J Reprod Med 2012;57:411-414)

• 出版日期2012-10